{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:43:05Z","timestamp":1781005385735,"version":"3.54.1"},"reference-count":55,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3456,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2002,8]]},"abstract":"<jats:p><jats:bold>Study Objective.<\/jats:bold> To evaluate the role of butalbital\u2010containing products in the management of migraine.<\/jats:p><jats:p><jats:bold>Methods.<\/jats:bold> Qualitative systematic search using MEDLINE (January 1966\u2013November 2001), review of the United States Headache Consortium's evidence\u2010based guidelines for migraine treatment, and review of other pertinent literature.<\/jats:p><jats:p><jats:bold>Results.<\/jats:bold> Over 28 million people suffer with migraine, yet this illness is less than optimally diagnosed and managed. Between 14% and 36% of diagnosed migraineurs are prescribed butalbital\u2010containing products, often as initial therapy. However, the only identified controlled trial of these drugs for migraine treatment showed that butalbital\u2010containing products were inferior to butorphanol. The consortium's guidelines specifically discourage administration of butalbital\u2010containing products for migraine. In addition, other published literature highlights the frequent adverse consequences of butalbital\u2010containing products for migraineurs, such as poor migraine control, disability, drug\u2010induced headaches, and withdrawal symptoms.<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> Although butalbital\u2010containing products commonly are prescribed for migraine, no evidence in the literature demonstrates their benefit over other agents or placebo. Drugs with proven migraine efficacy, as listed in the consortium's evidence\u2010based guidelines, should be prescribed instead.<\/jats:p>","DOI":"10.1592\/phco.22.12.1029.33595","type":"journal-article","created":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T06:52:36Z","timestamp":1086072756000},"page":"1029-1035","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Do Butalbital\u2010Containing Products Have a Role in the Management of Migraine?"],"prefix":"10.1002","volume":"22","author":[{"given":"Richard G.","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Sarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007638.x"},{"issue":"7","key":"e_1_2_1_3_2","first-page":"1","article-title":"Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain","volume":"8","author":"Headache Classification Committee of the International Headache Society.","year":"1988","journal-title":"Cephalalgia"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2001.01.821"},{"issue":"11","key":"e_1_2_1_5_2","first-page":"S25","article-title":"The impact of migraine: how this disorder affects us all","volume":"40","author":"Kaniecki R.G.","year":"2000","journal-title":"Consultant"},{"issue":"8","key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.159.8.813","article-title":"Burden of migraine in the United States","volume":"159","author":"Hu X.H.","year":"1999","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1993.hed3301029.x"},{"issue":"2","key":"e_1_2_1_8_2","first-page":"S29","article-title":"Impact of migraine and migraine therapy on productivity and quality of life","volume":"55","author":"Solomon G.D.","year":"2000","journal-title":"Neurology"},{"issue":"11","key":"e_1_2_1_9_2","first-page":"S13","article-title":"Migraine: changing perspectives on pathophysiology and treatment","volume":"40","author":"Cady R.K.","year":"2000","journal-title":"Consultant"},{"issue":"4","key":"e_1_2_1_10_2","first-page":"S47","article-title":"Migraine: patterns of health care use","volume":"44","author":"Stang P.E.","year":"1994","journal-title":"Neurology"},{"issue":"4","key":"e_1_2_1_11_2","first-page":"S63","article-title":"Migraine: identifying and removing barriers to care","volume":"44","author":"Lipton R.B.","year":"1994","journal-title":"Neurology"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.6.754"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1999.00006.x"},{"key":"e_1_2_1_14_2","first-page":"105","article-title":"Migraine headaches: implications for management from a nationwide patient survey","volume":"11","author":"Adelman J.U.","year":"2000","journal-title":"Headache Q"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1979.hed1907370.x"},{"key":"e_1_2_1_16_2","volume-title":"Fiorinal (butalbital, aspirin, caffeine) product information","author":"Novartis Pharmaceuticals.","year":"2001"},{"key":"e_1_2_1_17_2","volume-title":"Fioricet (butalbital, acetaminophen, caffeine) product information","author":"Novartis Pharmaceuticals.","year":"2001"},{"key":"e_1_2_1_18_2","volume-title":"Esgic (butalbital, acetaminophen, caffeine) product information","author":"Forest Pharmaceuticals.","year":"2001"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198002213020806"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007646.x"},{"issue":"3","key":"e_1_2_1_21_2","first-page":"260","article-title":"Prescription drug use of newly diagnosed migraine headache sufferers in Olmsted County, Minnesota","volume":"42","author":"Osterhaus J.T.","year":"1992","journal-title":"Neurology"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02053.x"},{"key":"e_1_2_1_23_2","volume-title":"Imitrex (sumatriptan) product information","author":"Glaxo Wellcome.","year":"2001"},{"key":"e_1_2_1_24_2","volume-title":"Amerge (naratriptan) product information","author":"Glaxo Wellcome.","year":"2001"},{"key":"e_1_2_1_25_2","volume-title":"Zomig (zolmitriptan) product information","author":"Zeneca Pharmaceuticals.","year":"2001"},{"key":"e_1_2_1_26_2","volume-title":"Maxalt (rizatriptan) product information","author":"Merck & Co.","year":"2001"},{"key":"e_1_2_1_27_2","volume-title":"Migranal (dihydroergotamine) product information","author":"Novartis Pharmaceuticals.","year":"2001"},{"key":"e_1_2_1_28_2","volume-title":"Axert (almotriptan) product information","author":"Pharmacia.","year":"2002"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3807516.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.01189.x"},{"key":"e_1_2_1_31_2","volume-title":"Data on file","author":"Glaxo Wellcome","year":"2001"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A336"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.20.2599"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80083-1"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2001.01157.x"},{"key":"e_1_2_1_36_2","first-page":"37","article-title":"Stepping up to stratified care for migraine headaches: MCOs that embrace severity and control needs can cut costs and improve outcomes over time","author":"Mulligan M.","year":"1998","journal-title":"Manage Health Care"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102498018S2208"},{"issue":"1","key":"e_1_2_1_38_2","first-page":"S29","article-title":"The role of headache\u2010related disability in migraine management","volume":"56","author":"Lipton R.B.","year":"2001","journal-title":"Neurology"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18184"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(05)70302-9"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041006573.x"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00052.x"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199513030-00001"},{"key":"e_1_2_1_44_2","first-page":"207","article-title":"Rebound headaches: a review","volume":"10","author":"Warner J.S.","year":"1999","journal-title":"Headache Q"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1990.hed3010634.x"},{"key":"e_1_2_1_46_2","first-page":"278","article-title":"Medication overuse [abstr]","volume":"21","author":"Diener H.C.","year":"2001","journal-title":"Cephalalgia"},{"issue":"3","key":"e_1_2_1_47_2","first-page":"S25","article-title":"Recurrent migraine: cost\u2010effective care","volume":"44","author":"Rapoport A.M.","year":"1994","journal-title":"Neurology"},{"issue":"3","key":"e_1_2_1_48_2","first-page":"S13","article-title":"Migraine: a pharmacologic review with newer options and delivery modalities","volume":"44","author":"Baumel B.","year":"1994","journal-title":"Neurology"},{"issue":"3","key":"e_1_2_1_49_2","first-page":"S18","article-title":"Chronic headache: appropriate use of opiate analgesics","volume":"44","author":"Markley H.G.","year":"1994","journal-title":"Neurology"},{"issue":"7","key":"e_1_2_1_50_2","first-page":"S6","article-title":"Overview of diagnosis and treatment of migraine","volume":"44","author":"Silberstein S.D.","year":"1994","journal-title":"Neurology"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1979.hed1903185.x"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1977.hed1701012.x"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1990.hed3008491.x"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1993.10472291"},{"key":"e_1_2_1_55_2","first-page":"47","article-title":"Acute barbiturates\u2010withdrawal syndrome: report of three atypical cases","volume":"9","author":"Coppola A.","year":"1998","journal-title":"Headache Q"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1996.3602119.x"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.22.12.1029.33595","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.22.12.1029.33595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:08:03Z","timestamp":1761059283000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.22.12.1029.33595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["10.1592\/phco.22.12.1029.33595"],"URL":"https:\/\/doi.org\/10.1592\/phco.22.12.1029.33595","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}